nference is a science-first software company that focuses on transforming unstructured data from electronic medical records (EMR) into powerful software solutions in the healthcare and life sciences industry. The company's main services include the development of software products that enable the synthesis of biomedical information, the creation of AI-enabled solutions for healthcare, and the provision of tools that unlock insights from structured and unstructured patient records. nference primarily sells to the healthcare ecosystem, with a focus on medical centers and biopharmaceutical companies. It was founded in 2013 and is based in Cambridge, Massachusetts.
ESPs containing nference
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The biomedical natural language processing (NLP) market holds immense significance for various stakeholders in the healthcare and life sciences. It utilizes advanced algorithms and linguistic models to extract and analyze information from vast amounts of biomedical text data such as scientific literature, electronic health records, and clinical trial reports. By leveraging biomedical NLP solutions…
Research containing nference
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned nference in 4 CB Insights research briefs, most recently on Aug 10, 2023.
Expert Collections containing nference
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
nference is included in 5 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health 150
The winners of the second annual CB Insights Digital Health 150.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Precision Medicine Tech Market Map
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
Drug Discovery Tech Market Map
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Latest nference News
Oct 23, 2023
Major Players Shaping the AI in Clinical Trials Market Key players in the AI in clinical trials market include Medable Inc., PathAI inc., Saama Technologies Inc., Apellis Pharmaceuticals Inc., TriNetX LLC, SymphonyAI Summit Inc., Aktana, Nference Inc., Insilico Medicine Inc., Vineti Inc., Innoplexus AG, Healx, AiCure Inc. Revolutionizing Clinical Trials with Innovative Products The AI in clinical trials market is witnessing a significant trend toward innovative product offerings. Leading companies in this sector are introducing groundbreaking products to maintain their competitive edge. For example, in January 2023, Elligo Health Research Inc., a US-based healthcare-enabling research organization, unveiled DataAI Connect, a cutting-edge data and technology platform designed to facilitate data-driven clinical research. This comprehensive platform simplifies data collection, management, analysis, and sharing of real-world patient data. Get A Free Sample Of The Global Artificial Intelligence (AI) In Clinical Trials Market Report Regional Dynamics and Market Segmentation In 2022, North America emerged as the largest region in the AI in clinical trials market and is expected to be the fastest-growing region in the forecast period. The global artificial intelligence (AI) in clinical trials market is meticulously segmented across various dimensions: By Offering: Software, Services By Process: Trial Design, Patient Selection, Site Selection, Patient Monitoring By Application: Oncology, Neurological Disease and Condition, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology Disease, and Other Applications By End-User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Other End-Users The Global AI in Clinical Trials Market Report 2023 is an invaluable resource for a diverse range of stakeholders. Businesses can leverage the insights within the report to make informed strategic decisions, identify avenues for growth, and align their strategies with evolving market dynamics. Investors will find the report essential for pinpointing areas of potential investment and forecasting future market trends. In summary, the artificial intelligence (AI) in clinical trials market report empowers stakeholders from various sectors to navigate the complex landscape of AI in clinical trials with confidence. Artificial Intelligence (AI) In Clinical Trials Global Market Report 2023 by The Business Research Company provides insights on the artificial intelligence (AI) in clinical trials market size, artificial intelligence (AI) in clinical trials market segments, artificial intelligence (AI) in clinical trials market trends, drivers and restraints, major competitors’ market positioning, revenues and market shares. The Business Research Company has published over 6,500+ industry reports, covering more than 2,500+ market segments and 60 geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. Check Out Similar Market Intelligence Reports By The Business Research Company: Artificial Intelligence Services Global Market Report 2023 Learn More About The Business Research Company The Business Research Company is a market intelligence firm pioneering in company, market, and consumer research. With offices all around the world, TBRC has specialist consultants in a variety of fields, including manufacturing, healthcare, financial services, chemicals, and technology. Global Market Model – World’s Most Comprehensive Database The Business Research Company’s flagship product, Global Market Model , is a market intelligence platform covering various macroeconomic indicators and metrics across 58 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps. Contact Data The Business Research CompanyEurope: +44 207 1930 708Asia: +91 8897263534Americas: +1 315 623 0293Email: firstname.lastname@example.orgFollow us on:LinkedIn: https://in.linkedin.com/company/the-business-research-companyTwitter: https://twitter.com/tbrc_infoFacebook: https://www.facebook.com/TheBusinessResearchCompanyYouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQBlog: https://blog.tbrc.info/Healthcare Blog: https://healthcareresearchreports.com/Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
nference Frequently Asked Questions (FAQ)
When was nference founded?
nference was founded in 2013.
Where is nference's headquarters?
nference's headquarters is located at One Main Street, Suite 400, Cambridge.
What is nference's latest funding round?
nference's latest funding round is Unattributed.
How much did nference raise?
nference raised a total of $146.34M.
Who are the investors of nference?
Investors of nference include Matrix Partners, Mayo Clinic Ventures, Matrix Capital Management and NTT Venture Capital.
Who are nference's competitors?
Competitors of nference include Causaly, Biorelate, Tempus, Amplion, Owkin and 7 more.
Compare nference to Competitors
Standigm is an AI-driven drug discovery company operating in the pharmaceutical industry. The company's main services include the use of proprietary AI platforms for novel target identification, lead generation, and the creation of commercially valuable drug pipelines. Standigm primarily sells to the pharmaceutical and healthcare industries. It was founded in 2015 and is based in Seoul, South Korea.
Aitia is a company focused on the development and application of Causal AI and Digital Twins in the pharmaceutical industry. The company's main services include the discovery of drugs for neurodegenerative disorders, oncology, and immunology by revealing hidden biological mechanisms of diseases and creating Digital Twins. These Digital Twins are used to discover novel therapies and accelerate research and development in various diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer. It was founded in 2000 and is based in Cambridge, Massachusetts.
Aetion operates as a healthcare analytics company. It provides decision-grade real-world evidence solutions to biopharma companies, payers, and regulatory agencies. It offers a platform that analyzes data from the real world to produce scientifically validated answers on treatments, effectiveness, and value. The company was founded in 2012 and is based in New York, New York.
Atomwise develops machine learning-based discovery engines and uses deep learning and artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. The company was founded in 2012 and is based in San Francisco, California.
Healx provides drug discovery services. The company manufactures drugs using technology to bring treatments for rare diseases to patients. Its platform, Healnet, helps face challenges by analyzing drug and disease data points. The company was founded in 2014 and is based in Cambridge, U.K.
Aria Pharmaceuticals is a preclinical-stage pharmaceutical company that focuses on the discovery and development of novel, small molecule therapies in the pharmaceutical industry. The company's main service is the development of new treatments for complex and hard-to-treat diseases using their proprietary Symphony platform, which combines biomedical data and artificial intelligence to increase the success rates of drug discovery. Aria Pharmaceuticals primarily serves the healthcare sector, specifically targeting areas where new therapies are most needed. It was founded in 2014 and is based in Palo Alto, California.